Completes enrollment of prospective study (BLADE) to advance second software-based AXINON® IVD test
Regensburg, Germany, 13 July 2017 – numares AG obtained promising results from a retrospective study that provides initial evidence that evaluation of metabolomic biomarker networks can be used as a non-invasive diagnostic for bladder cancer. Based on these results, the company enrolled patients in a prospective study to confirm and further refine the metabolomic network. The test is intended to be launched as a CE-marked in-vitro diagnostics (IVD) in Europe in the second half of 2018.
